Journal article
Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
Abstract
BackgroundAnti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma.Case presentationA 62-year old woman diagnosed with severe eosinophilic asthma showed poor response to Mepolizumab therapy (100 mg subcutaneous dose/monthly) and subsequent worsening of symptoms. The treatment response to …
Authors
Mukherjee M; Lim HF; Thomas S; Miller D; Kjarsgaard M; Tan B; Sehmi R; Khalidi N; Nair P
Journal
Allergy, Asthma & Clinical Immunology, Vol. 13, No. 1,
Publisher
Springer Nature
Publication Date
December 2017
DOI
10.1186/s13223-016-0174-5
ISSN
1710-1484